Comparative Risk of Intracranial Hemorrhage With Tenecteplase Versus Alteplase in Acute Ischemic Stroke.

ABSTRACT: Background: In patients with acute ischemic stroke (AIS), tenecteplase and alteplase help preserve brain tissue. The 2019 American Heart Association/American Stroke Association guidelines designate alteplase as the first-line therapy for AIS, listing tenecteplase as a reasonable alternative for patients eligible for mechanical thrombectomy. The 2023 European Stroke Organisation recommends tenecteplase in patients with AIS due to large vessel occlusion prior to thrombectomy. Our institution adopted tenecteplase as the formulary fibrinolytic for AIS due to emerging clinical data, reduced cost, and operational benefits. Objective: The objective was to compare outcomes associated with tenecteplase versus alteplase in AIS. Methods: This multicenter, retrospective study incl

SUBMITTER: Hammaker K 

PROVIDER: S-EPMC12491217 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature